呼出一氧化氮bb0 300 ppb患者的呼吸衰竭，随后对dupilumab有反应。

Q3 Medicine

Baylor University Medical Center Proceedings Pub Date : 2024-08-28 eCollection Date: 2025-01-01 DOI:10.1080/08998280.2024.2395213

Howard Crisp

{"title":"呼出一氧化氮bb0 300 ppb患者的呼吸衰竭，随后对dupilumab有反应。","authors":"Howard Crisp","doi":"10.1080/08998280.2024.2395213","DOIUrl":null,"url":null,"abstract":"Multiple biologic agents are approved for the treatment of severe persistent asthma not controlled by inhaled corticosteroid/beta-agonist therapy. Appropriate phenotyping can aid in picking the right biologic for the right patient. Here is a unique case of a patient with severe asthma and respiratory arrest, with fraction of exhaled nitric oxide >300 ppb whose asthma became completely controlled with dupilumab.","PeriodicalId":8828,"journal":{"name":"Baylor University Medical Center Proceedings","volume":"38 1","pages":"81-84"},"PeriodicalIF":0.0000,"publicationDate":"2024-08-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11657067/pdf/","citationCount":"0","resultStr":"{\"title\":\"Respiratory failure in a patient with exhaled nitric oxide >300 ppb and subsequent response to dupilumab.\",\"authors\":\"Howard Crisp\",\"doi\":\"10.1080/08998280.2024.2395213\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Multiple biologic agents are approved for the treatment of severe persistent asthma not controlled by inhaled corticosteroid/beta-agonist therapy. Appropriate phenotyping can aid in picking the right biologic for the right patient. Here is a unique case of a patient with severe asthma and respiratory arrest, with fraction of exhaled nitric oxide >300 ppb whose asthma became completely controlled with dupilumab.\",\"PeriodicalId\":8828,\"journal\":{\"name\":\"Baylor University Medical Center Proceedings\",\"volume\":\"38 1\",\"pages\":\"81-84\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-08-28\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11657067/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Baylor University Medical Center Proceedings\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1080/08998280.2024.2395213\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/1 0:00:00\",\"PubModel\":\"eCollection\",\"JCR\":\"Q3\",\"JCRName\":\"Medicine\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Baylor University Medical Center Proceedings","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1080/08998280.2024.2395213","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/1 0:00:00","PubModel":"eCollection","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

摘要

多种生物制剂被批准用于治疗吸入皮质类固醇/ β激动剂治疗无法控制的严重持续性哮喘。适当的表型可以帮助为合适的患者选择合适的生物制剂。这是一个患有严重哮喘和呼吸骤停的患者的独特病例，呼出一氧化氮的分数为100 300 ppb，其哮喘在dupilumab的治疗下完全得到控制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Respiratory failure in a patient with exhaled nitric oxide >300 ppb and subsequent response to dupilumab.

Multiple biologic agents are approved for the treatment of severe persistent asthma not controlled by inhaled corticosteroid/beta-agonist therapy. Appropriate phenotyping can aid in picking the right biologic for the right patient. Here is a unique case of a patient with severe asthma and respiratory arrest, with fraction of exhaled nitric oxide >300 ppb whose asthma became completely controlled with dupilumab.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Baylor University Medical Center Proceedings Medicine-Medicine (all)

CiteScore

1.30

自引率

0.00%

发文量

245